Boehringer Ingelheim and Microsoft announced a collaboration to develop AI-powered “digital patient twins” for clinical trials. The initiative aims to simulate disease progression and treatment response by drawing from clinical and other data, with the goal of evaluating whether such models can support synthetic or hybrid control arms. The project is described as exploratory and at an early stage, and Boehringer said any potential trial use would require robust scientific validation and regulatory approval. The effort is positioned as a way to improve trial design and potentially reduce the number of control patients needed. The announcement aligns with broader industry momentum toward AI tooling in trial operations, including document automation and recruitment optimization collaborations. It also follows U.S. HHS efforts testing digital twins as part of trial feasibility work. For biotech development teams, the collaboration provides another route to reduce trial friction—while maintaining the evidentiary bar expected for regulatory-grade decision-making.